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Background: The mitotic kinase-encoding gene STK15/BTAK/
AuroraA is associated with aneuploidy and transformation
when overexpressed in mammalian cells. STK15 overexpres-
sion activates an unknown oncogenic pathway that involves
centrosome amplification and results in missegregation of
chromosomes. Because clinical prognosis and tumor aneu-
ploidy are tightly linked in human bladder cancer, we ex-
amined whether increased STK15 copy number and protein
levels are linked to aneuploidy in bladder cancers. Methods:
STK15 protein was visualized by immunohistochemistry in
205 formalin-fixed, paraffin-embedded human bladder tu-
mors. STK15 gene copy number was evaluated in 61 tumors
by Southern blot hybridization and in 21 of these 61 tumors
by fluorescence in situ hybridization (FISH). Copy numbers
of chromosomes 3, 17, 20, and 21 were evaluated by FISH
with chromosome-specific probes. STK15 expression levels
were related to histologic grade, stage, and DNA ploidy of
the tumors and to the patients’ follow-up data. The chi-
square test for association was used to analyze the relation-
ship between STK15 expression and pathologic features. All
statistical tests were two-sided. Results: Tumors with low
levels of STK15 amplification (3–4 copies) showed minimal
deviation in their chromosome copy number and diploid or
near-diploid total nuclear DNA content. Tumors with higher
levels of STK15 amplification (>4 copies) had a major in-
crease of chromosome copy number and of their total
nuclear DNA content, i.e., exhibited pronounced aneuploidy.
Elevated expression of STK15 was strongly associated with
parameters of clinical aggressiveness including high histo-
logic grade (P<.001), invasion (P<.001), increased rate of me-
tastasis (P<.001), and decreased metastasis-free (P<.001) and
overall (P<.001) survival of patients with bladder cancer.
Conclusion: STK15 gene amplification and associated in-
creased expression of the mitotic kinase it encodes are asso-
ciated with aneuploidy and aggressive clinical behavior in
human bladder cancer. [J Natl Cancer Inst 2002;94:
1320–9]
Numeric chromosomal aberrations or aneuploidy are the most
prevalent somatic alterations identified in solid human tumors
(1,2). Aneuploidy has been proposed to drive tumor progression
by enhancing genomic instability, resulting in alterations of cel-
lular phenotypes (3). This hypothesis has gained credibility in
view of recent reports showing that, during the process of trans-
formation, human and rodent cell lines display elevated rates of
chromosome instability and that aneuploidy precedes immortal-
ization (4–6). The degree of chromosomal instability and tumor
behavior are also strongly related. Tumors with minimal devia-
tion in chromosome copy number, i.e., near-diploid, are clini-
cally less aggressive than those with major deviation in chro-
mosome copy number—that is, with increases in total nuclear
DNA content resulting from extra copies of multiple chromo-
somes (7–12). Therefore, measurements of total nuclear DNA
content by image analysis or flow cytometry are frequently used
to assess the clinical aggressiveness of many solid human tu-
mors (13,14).
During normal cell proliferation, centrosomes ensure equal
segregation of chromosomes to the postmitotic daughter cells by
organizing the bipolar mitotic spindle. Cancer cells, by contrast,
frequently have multipolar mitotic spindles and various centro-
somal anomalies, such as supernumerary centrosomes, centro-
somes of abnormal size and shape, aberrantly phosphorylated
centrosomal proteins, and prematurely split centrosomes (15–
21). It is conceivable that such abnormalities would disrupt nor-
mal chromosomal segregation, producing aneuploid cells.
The molecular mechanisms of centrosome function, includ-
ing the pathways through which they regulate chromosomal seg-
regation, remain to be elucidated. However, a recently cloned
and characterized mitotic kinase-encoding gene, STK15/BTAK/
AuroraA (22,23), has been implicated in the regulation of cen-
trosome duplication and has been reported to be frequently am-
plified/overexpressed in human tumors, suggesting that the
STK15 protein may represent a critical regulatory component of
chromosomal segregation that can cause aneuploidy and trans-
formation (23,24).
STK15 is a member of the serine/threonine kinase family that
includes the prototypic yeast IPL1 and Drosophila aurora ki-
nases, as well as other mammalian and nonmammalian aurora
kinases involved in regulating chromosomal segregation
(25,26). In yeast, the temperature-sensitive ipl1 gene mutants
missegregate chromosomes, resulting in polyploidy (27). Loss
of function of aurora kinases in Drosophila inhibits centrosome
separation, leading to formation of abnormal mitotic spindles
(26). STK15 has high homology with other aurora kinases (28).
In the present study, we attempted to relate the levels of
STK15 gene amplification and/or overexpression with the de-
gree of aneuploidy and the biologic behavior of human bladder
tumors in vivo. Bladder tumors are among the most common
human cancers, with approximately 55 000 new cases detected
each year in the United States. Bladder cancers, which represent
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a group of tumors with diverse morphologic and clinical behav-
ior, exhibit one of the strongest relationships seen in any cancer
between clinical aggressiveness and degree of aneuploidy (29–
31). Bladder cancers arise from at least two distinct, albeit some-
times overlapping, pathways that lead to the development of
papillary and solid or nonpapillary tumors (31,32). Most super-
ficially growing, low-grade papillary lesions are diploid or near-
diploid. Although they often recur, they are unlikely to invade
the bladder wall and metastasize. By contrast, virtually all non-
papillary tumors are highly aneuploid and have a strong propen-
sity to invade the stroma and metastasize. Superficial bladder
tumors that are aneuploid are also likely to progress to invasive
clinically aggressive carcinomas, which may metastasize. In this
study, we used human bladder tumors as a model system to
determine whether higher than normal STK15 gene copy num-
ber and/or protein expression levels are linked to aneuploid,
clinically aggressive variants of bladder cancer.
MATERIALS AND METHODS
Tumor Samples
These studies were conducted on a retrospective cohort of
205 patients with urinary bladder carcinoma who were treated
and/or followed at The University of Texas M. D. Anderson
Cancer Center. All patients had primary urothelial carcinomas of
the bladder, and none of the patients whose tumor samples were
used in this study had received prior chemotherapy or radio-
therapy. The patients ranged in age from 37 years to 85 years
(mean 71 years). One hundred fifty-four patients were male and
51 were female. Fresh tumor tissues were obtained by transure-
thral resection or from cystectomy specimens and were stored
at –70 °C. Tumor samples and follow-up data were obtained
according to The University of Texas M. D. Anderson Cancer
Center Institutional Review Board-approved laboratory protocol.
For processing, the frozen tissue samples were sectioned,
stained with hematoxylin–eosin, and evaluated microscopically.
Portions of tissue containing almost pure tumor cells were mi-
crodissected from the frozen block and used for preparation of
touch prints (31). One portion of the tumor tissue was fixed in
formalin, embedded in paraffin, and sectioned (4 m thick) for
use in microscopic assessment of the tumor and immunohisto-
chemical studies of STK15 expression; another was used for
DNA extraction. The tumors were classified according to the
three-tier World Health Organization histologic grading system,
growth pattern (papillary versus nonpapillary), and DNA ploidy
(33). The depth of invasion was recorded according to the TNM
(Tumor–Node–Metastasis) staging system (34). Stage T1
(lamina propria invasion) has been divided into T1a (no muscu-
laris mucosae invasion) and T1b (muscularis mucosae invasion),
which have a clinically significant higher risk of progression
(35). Consequently, the tumors were dichotomized into superfi-
cial (Ta–T1a) and invasive (T1b and higher) groups. Of 205 blad-
der tumors, 104 were classified low-grade (grade 1–2) and 101
were high-grade (grade 3).
Paraffin-embedded tumor tissue from all 205 patients was
used to analyze the relationship between STK15 expression and
pathologic parameters of the tumors and clinical follow-up data.
For 61 of the tumor samples, extracted genomic DNA was avail-
able for Southern blot hybridization analysis of STK15 gene
copy number. For 21 of these 61 tumor samples, touch prints
from the fresh tumor samples were used for quantitative fluo-
rescence in situ hybridization (FISH) of the STK15 gene and
selected chromosomes (3, 17, 20, and 21) copy number analysis.
For DNA ploidy measurements, touch prints of tumor tissue
and slides of a diploid standard (human peripheral blood lym-
phocytes from healthy volunteers) were fixed in 10% neutral
buffered formalin and stained with the Feulgen reaction (31).
Total nuclear DNA content in individual tumor cells was mea-
sured by visual inspection with the SAMBA 4000 (Ampersand
Medical, Chicago, IL) computer-assisted image analysis system.
Frequency histograms of DNA content were generated on the
basis of measurements from 200 to 300 morphologically iden-
tifiable intact tumor nuclei. The DNA index was calculated as
the ratio of the mean nuclear DNA content of the tumor cells to
the mean nuclear DNA content of peripheral blood lymphocytes.
Tumors with DNA indices ranging from 0.9 to 1.2 were classi-
fied as diploid/near-diploid; tumors in which more than 20% of
cells formed a distinct peak on the histogram with a DNA index
of greater than 1.2 were classified as aneuploid. The aneuploid
bladder tumors with DNA index greater than 1.2 have more
aggressive clinical behavior than diploid/near-diploid tumors
and have a higher risk for progression and development of dis-
tant metastases (31).
Immunohistochemical Analysis of STK15 Expression
A rabbit polyclonal anti-STK15 antibody developed in our
laboratory and raised against a carboxy terminal peptide was
used for immunohistochemical localization of STK15 protein
expression in the tumor tissues as described (23,36). Slides of
formalin-fixed, paraffin-embedded tissue sections were de-
paraffinized, rehydrated, and then digested with 0.05% trypsin.
After blocking in 15% (vol/vol) normal goat serum, the slides
were first incubated at room temperature with anti-STK15 anti-
body (diluted 1 : 40 in phosphate-buffered saline [PBS]) and then
with biotinylated goat anti-rabbit immunoglobulin G (IgG) an-
tibody (Vector Laboratories, Burlingame, CA) (diluted 1 : 200 in
PBS). The bound antibodies were detected by the avidin–biotin–
peroxidase complex assay (Vector Laboratories) and were visu-
alized with the chromogen amino-ethyl carbazole (Sigma
Chemical Co., St. Louis, MO). Semiquantitative evaluation of
the staining intensity for immunohistochemical localization of
STK15 was performed by three investigators (B. Czerniak,
S. Sen, F. Vakar-Lopez) independently in a blinded manner. The
intensity of immunohistochemical staining was scored on a
three-point scale as follows: –, no detectable expression; +, weak
to moderate expression; ++, strong expression. The tumors were
classified as positive for STK15 overexpression when more than
20% of the cells showed strong cytoplasmic expression, as has
been conventionally done in other studies (35). Paraffin-
embedded tumor sections of a human breast carcinoma cell line
(MCF7) with known eightfold amplification of the STK15 gene
and overexpression of the STK15 protein identified in our pre-
vious study were used as positive controls (36). The baseline
expression level of STK15 protein in normal urothelium was
determined by using sections of paraffin-embedded normal ure-
ters obtained from nephrectomy specimens.
STK15 Copy Number Analysis by Southern Blot
Hybridization
Southern blot hybridizations using the STK15 cDNA probe
developed in our laboratory (36) were performed on BamHI-
digested total genomic DNA (10 g per sample) from 61 tu-
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mors, according to a previously described standard protocol
(23,36). The STK15 cDNA probe identifies three DNA bands, of
13.5 kb, 9.4 kb, and 7.9 kb. We measured the signal intensity of
the 13.5-kb band, representing the STK15-specific sequence,
and the signal intensity of the 7.9-kb band, representing an un-
amplified STK15–pseudogene sequence, by PhosphorImager
analysis using a Storm 860 system (Molecular Dynamics, Sun-
nyvale, CA). To assess the STK15 gene copy number, the ratio
of the signal intensities of these two bands for each tumor
sample was compared with the ratio obtained from normal lym-
phocyte DNA that was run on the same gel. BamHI-digested
MCF7 DNA was used as a positive control.
STK15 Gene Amplification Detected by FISH
FISH analyses were performed on 21 touch prints of 61 fro-
zen tumor tissues. The STK15 probe contained in a 3B23 bac-
terial artificial chromosome clone identified in our laboratory
was co-hybridized with D20S894, a chromosome 20p arm-
specific probe (provided by Dr. Joe Gray, University of Califor-
nia, San Francisco) as previously described (23). Briefly, the
STK15 probe was labeled with digoxigenin, and the D20S894
probe was labeled with biotin. After hybridization to the tumor
tissues, the bound probes were detected with fluorescein isothio-
cyanate-conjugated mouse anti-digoxigenin antibody (Sigma
Chemical Co.) and Cy3-labeled streptavidin (Amersham Phar-
macia, Piscataway, NJ), respectively.
Chromosome 3, 17, and 21 copy numbers in interphase tumor
nuclei were analyzed in the same 21 tumor samples by FISH
with chromosome-specific centromeric probes (Vysis, Abbott
Park, IL). Quantitative FISH analysis was performed with fluo-
rescence microscopy by counting hybridization signals in 100–
200 intact tumor nuclei. Normal human urothelial cells from
nephrectomy specimens resected for renal carcinoma were used
both to test the performance of FISH probes in normal human
diploid tissue and to serve as a negative control. All images were
collected on a Leica DMRXA fluorescence microscope
equipped with a high-resolution, high-sensitivity Hamamatsu
CCD camera (model No. C4742-95-12; Hamamatsu Photonics
K.K., Sunayama-CHO, Hamamatsu-city, Japan) and were digi-
tally processed by using Openlab imaging software (Improvi-
sion, Boston, MA). Complete quantitative data on STK15 and
chromosome 3, 17, 20, and 21 copy numbers were obtained for
16 of the 21 tumors. Only partial quantitative FISH data could be
obtained from the remaining five tumors because of technical
problems.
Cell Culture and Western Blot Analysis
Nu201 normal human urothelial cells were derived in our
laboratory from primary cultures of normal ureters removed dur-
ing nephrectomy for renal carcinoma (37). The UC14 cell line
was derived in our laboratory from a highly aneuploid grade 3
nonpapillary urothelial carcinoma of the bladder (38,39). Cells
were cultured in serum-free keratinocyte medium (Life Tech-
nologies Inc., Carlsbad, CA) containing 0.04 M calcium.
The specificity of the anti-STK15 antibody was verified by
western blot analysis of total protein lysates prepared from
Nu201 and UC14 cells grown in vitro. Subconfluent cell mono-
layers were lysed in extraction buffer as described (23). Lysates
containing approximately 100 g of total cell protein were
loaded onto 125% sodium dodecyl sulfate—polyacrylamide gel
electrophoresis (SDS–PAGE)–10% Tris–glycine gels (NOVEX;
Invitrogen, Carlsbad, CA), subjected to electrophoresis, and
transferred by electroblotting (BioRad, Hercules, CA) to nitro-
cellulose membranes. The membranes were first blocked in 5%
bovine calf serum (BCS) in 10 mM Tris, 150 mM NaCl, 0.05%
Tween 20 (TBST) and then incubated either with the affinity-
purified rabbit polyclonal anti-STK15 antibody (1 : 400 dilution
in 0.5% BCS in TBST) or with the antibody preincubated with
the cognate peptide against which it was raised (0.1 mg of an-
tibody to 1 mg of peptide). The STK15 protein band was de-
tected with a peroxidase-conjugated anti-rabbit secondary anti-
body (Amersham) and visualized with the use of the enhanced
chemiluminescence (ECL)-Plus (Amersham) detection system.
Finally, western blots were stripped and reincubated with a pri-
mary mouse monoclonal anti--actin antibody (Amersham)
(1 : 300 in 5% BCS in TBST) and a secondary peroxidase-
conjugated anti-mouse antibody (Amersham) to normalize the
amount of protein loaded in each lane.
Statistical Analysis
The relationship between expression and amplification levels
of STK15 and various clinicopathologic parameters was ana-
lyzed using chi-square and Student’s t tests. Continuous mea-
sures, such as STK15 expression, were analyzed both with and
without logarithmic transformation, with similar results for each.
Sample sizes were large enough to permit parametric tests.
Where appropriate, the associated nonparametric tests were also
performed and yielded similar results to the parametric tests. The
expression levels of STK15 in relation to time between diagno-
sis and recurrence, to time between diagnosis and metastasis,
and to overall survival were tested by Kaplan–Meier analysis by
the Gehan–Wilcoxon and Peto log-rank tests (40). Correlation
between STK15 and chromosome copy number estimated by
FISH was analyzed by the Spearman’s rank correlation coeffi-
cient (41). Statistical analyses were performed by using Statis-
tica software (StatSoft, Inc., Tulsa, OK) and Statistical Package
for Social Scientists Software (SPSS Inc., Chicago, IL). In all
statistical analyses, two-sided P values .05 were considered
statistically significant.
RESULTS
This study was designed to investigate whether increased
STK15/BTAK/AuroraA copy number and protein levels are
linked to chromosomal instability and aneuploidy in human
bladder cancer. STK15 copy number was initially analyzed by
Southern blot hybridization of genomic DNA from tumor tissues
representing various pathologic subsets, grades, and stages of
the disease (representative results are shown in Fig. 1, a). To
determine whether STK15 was amplified, we measured the ratio
of the hybridization signal intensities of the 13.5-kb and 7.9-kb
bands (Fig. 1, a) for each tumor and normalized this ratio to the
ratio of the hybridization signal intensities of the same bands
obtained from normal peripheral blood lymphocytes. The
STK15 gene was amplified two- to sevenfold in 35% of high-
grade (grade 3) invasive urothelial carcinomas with pronounced
aneuploidy (data not shown). Examples of STK15 amplification
identified by Southern blot hybridization are shown in Fig. 1, a
(lanes 15–19). No STK15 amplification was identified in low-
grade (grades 1–2) superficial papillary tumors that were dip-
loid/near-diploid (i.e., that showed only a minor increase in their
total DNA content, with a DNA index of 1–1.2).
1322 ARTICLES Journal of the National Cancer Institute, Vol. 94, No. 17, September 4, 2002
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on A
ugust 9, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
To determine STK15 protein expression levels in tumor tis-
sues, we used a specific anti-STK15 antibody (Fig. 1, b) to
perform immunohistochemistry (Fig. 1, c). The semiquantitative
expression levels were subsequently related to the total nuclear
DNA contents (ploidy) (Fig. 1, d). The STK15 protein was over-
expressed, defined as strong positive staining in more than 20%
of tumor cells in all of the 10 bladder tumors identified by
Southern blotting as having increased STK15 gene copy number
(data not shown) and in an additional 46% of the high-grade
aneuploid carcinomas with no evidence of gene amplification
(data not shown). In low-grade (grades 1–2) superficial papillary
tumors that were diploid/near-diploid (Fig. 1, d, left panel),
minimal levels of STK15 expression were typically detected
(Fig. 1, c, left panel). In general, there was no difference in the
intensity of staining among normal urothelium, bladder wall
stromal tissue, and low-grade superficial papillary tumors (data
not shown).
These data suggested that STK15 protein overexpression was
associated with high-grade aneuploid tumors and could occur in
the absence of gene amplification. However, it is possible that
STK15 gene amplification occurred in only a proportion of the
tumor cells and was not detected by Southern blot analysis. It is
also possible that an increase in STK15 gene copy number was
the result of multiple copies of chromosome 20, on which the
Fig. 1. Analysis of STK15 copy number,
protein expression, and DNA ploidy in hu-
man bladder cancers. a) Genomic DNA was
isolated from 61 human bladder cancers, di-
gested with the restriction enzyme BamHI,
and analyzed for STK15 gene amplification
by Southern blot hybridization. Representa-
tive results from 19 tumors are shown. Dif-
ferences in signal intensity (signal ratio) be-
tween the top band of approximately 13.5 kb,
which represents STK15-specific sequences,
and the bottom band of approximately 7.9
kb, which represents unamplified sequences
of a pseudogene, were normalized to the sig-
nal ratio from BamHI-digested normal hu-
man peripheral blood lymphocyte DNA
(lane N) and used to estimate gene copy
number. The signal ratios are given below
each lane. BamHI-digested DNA from the
MCF7 human breast tumor cell line, which
has a high level of STK15 amplification
(36), was used as a positive control. Tumor
case numbers are shown above each lane.
The size of each DNA band (in kb) is shown
to the right of the figure. Immunohistochem-
ical detection of overexpressed STK15 pro-
tein is indicated by a + below each lane.
After staining the samples with the Feulgen
reaction (13), the DNA content was deter-
mined by generating frequency histograms
with the SAMBA 4000 computer-assisted
image analysis system. DNA indices were
calculated by comparing the DNA content of
the tumor sample with the DNA content of a
diploid standard (human peripheral blood
lymphocytes from healthy volunteers). Tu-
mors with DNA indices ranging from 0.9 to
1.2 were classified as diploid/near-diploid;
tumors in which more than 20% of cells
formed a distinct peak on the histogram with
a DNA index of greater than 1.2 were clas-
sified as aneuploid. b) Western blot analysis
of STK15 expression in Nu201 normal hu-
man urothelial cells and in the aneuploid
UC14 bladder cancer cell line using a rabbit
polyclonal anti-STK15 antibody (36). The
specificity of the antibody is seen from the
detection of a single protein band in the top panel and the absence of any band in the middle panel in which the antibody was blocked by the peptide antigen against
which the antibody was made. The presence of similar intensity -actin bands in both lanes in the lower panel indicates that comparable amounts of proteins were
loaded from the two cell types. c) Representative immunohistochemical staining of STK15 expression in human bladder cancers with the rabbit polyclonal
anti-STK15 antibody. The antibody–antigen complexes were detected by using the avidin–biotin–peroxidase method and amino-ethyl carbazole as the chromogen.
The slides were counterstained with hematoxylin. Left panel, immunohistochemical staining of tumor No. 3, a diploid/near-diploid low-grade papillary urothelial
carcinoma showing minimal expression of STK15. Right panel, immunohistochemical staining of tumor No. 15, an aneuploid high-grade invasive nonpapillary
urothelial carcinoma showing strong overexpression of STK15. Solid bar indicates 50 m. d) DNA histograms generated by measurements of total nuclear DNA
content of Feulgen-stained human bladder cancer cells of diploid/near-diploid tumor No. 3 (left panel) and aneuploid tumor No. 15 (right panel).
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STK15 gene resides, and not bona fide amplification of the
STK15 gene alone. To distinguish between these possibilities,
dual-color FISH analysis on bladder tumor tissue touch prints
was performed.
For this analysis, tumor cells were co-hybridized with an
STK15-containing genomic bacterial artificial chromosome
probe and a probe for the p arm of chromosome 20. To assess the
relationship between levels of STK15 amplification and overall
aneuploidy, sequential touch prints from the same tumors were
hybridized with centromeric probes for chromosomes 3, 17, and
21. These studies allowed us to identify the exact levels of
STK15 gene amplification and to detect small populations of
aneuploid cells and/or gene amplification in otherwise predomi-
nantly diploid tumor tissues. The STK15 gene amplification
estimates by Southern blotting and FISH, the immunohisto-
chemical gene expression levels, and the degree of aneuploidy
measured as the DNA index of total nuclear content in the 16
bladder tumors for which we could obtain these data are listed in
Table 1. The patterns of signal distribution in individual nuclei
(representative images are shown in Fig. 2, a–d) exemplify the
various STK15 gene copy number and chromosome 20 ploidy
alterations. The presence of two discrete signals for each probe
reflected normal chromosome 20 disomy and a diploid STK15
gene copy number (Fig. 2, a). More than two STK15 signals in
the presence of two signals for the chromosome 20p-arm probe
indicated that the gene was amplified in tumor cells (Fig. 2, b
and c). The same number of signals, but more than two for both
probes, indicated polysomy for chromosome 20 (Fig. 2, d).
Using the patterns of signal distribution, the 16 tumors were
classified according to their levels of STK15 gene amplification
and chromosomal ploidy status (Fig. 2, e and f). We found that
an increase of STK15 gene copy number was ubiquitous in
bladder tumors: at least a minimal level (three to four copies) of
gene amplification involving a fraction of the tumor cell popu-
lation could be identified in every bladder cancer tested. There
were, however, striking differences in the levels of STK15 gene
amplification between diploid/near-diploid and highly aneuploid
tumors. In diploid/near-diploid tumors, approximately 40%–
50% of the tumor cells contained three to four copies of the
STK15 gene, and only about 2%–20% of the tumor cells con-
tained more than four copies of the STK15 gene (Fig. 2, e). By
contrast, highly aneuploid tumors were characterized by the
presence of at least 20% of the tumor cells containing more than
four copies of the STK15 gene (Fig. 2, e). Such relationships
were observed in all (9 of 10) but one of the tested cases in
which strong overexpression of STK15 was associated with pro-
nounced aneuploidy but not with a major increase in gene copy
number (Fig. 2, e and f, case 16). This case supports our previous
observations implicating another mechanism involved in in-
creased STK15 gene expression in the absence of STK15 gene
amplification (23).
For some tumors, the prominent tumor cell population con-
tained an increased STK15 copy number, primarily due to poly-
somy of chromosome 20 (Fig. 2, d). Overall, high levels of
STK15 amplification were associated with a major increase in
total nuclear DNA content and chromosomal copy number (Fig.
2, g and h). By contrast, tumors with low levels of STK15
amplification showed only a minimal increase in chromosomal
copy number and total nuclear DNA content (Fig. 2, g and h).
Overall, these data suggest that the degree of aneuploidy is pro-
portional to the level of STK15 gene amplification (Spearman’s
correlation coefficient, r  .82) (Fig. 2, i).
Table 1. Comparison of STK15 gene copy estimates by fluorescence in situ hybridization (FISH) and Southern blotting, immunohistochemical expression levels
of STK15 protein, and DNA ploidy in 16 bladder tumors classified according to their histologic grade, pathogenetic subset, and stage*
Case No.
STK15 copy No.
STK15 protein
expression‡
DNA ploidy§
(DNA index)
Histologic grade and
pathogenetic subset Stage¶
% of cells by FISH
By Southern blotting†3–4 copies >4 copies
1 42 2 – – 1.2 2(P) T1a
2 32 2 – – 1.2 2(P) Ta
3 36 4 – – 1.1 2(P) Ta
4 38 7 – – 1.1 2(P) T2
5 50 13 – – 1.2 2(P) T1a
6 47 18 – – 1.3 2(P) T1a
7 47 22 – – 2.2 3(NP) T3
8 54 24 – + 2.8 3(NP) T3
9 55 32 – + 2.9 3(NP) T4
10 50 55 – + 2.3 3(NP) T3
11 36 60 + (2.5) + 2.1 3(NP) T3
12 25 67 + (2.5) + 4.6 3(NP) T3
13 22 70 + (3) + 3.1 3(P) T3
14 10 83 + (3) + 3.7 3(NP) T3
15 14 86 + (5) + 3.2 3(P) T2
16 63 2 – + 1.7 3(NP) T3
*P  papillary; NP  nonpapillary.
†+ indicates increased gene copy number documented by Southern blotting. Numbers in parentheses designate the increased gene copy number based on
densitometric analyses of STK15 gene-specific fragment in reference to an unamplified internal control genomic DNA fragment detected on the same Southern blots.
– indicates that no increased gene copy number could be documented by Southern blotting.
‡+ indicates immunohistochemical evidence of STK15 overexpression in at least 20% of tumor cells. – indicates that no overexpressed STK15 protein level could
be documented in at least 20% of tumor cells.
§DNA index  the ratio of total nuclear DNA content of tumor cells to that of a diploid standard. The tumors with a DNA index of 0.9–1.2 were classified as
diploid/near-diploid. The tumors with a DNA index of greater than 1.2 were classified as aneuploid.
Histologic grading is according to World Health Organization (WHO) grading system for bladder tumors (33).
¶Tumors were staged according to the Tumor–Node–Metastasis (TNM) classification of malignant tumors with T1a–b substaging (34,35).
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We next tested whether the correlation between STK15 gene
amplification levels and aneuploidy could be used as a marker to
identify clinically aggressive bladder cancers and whether im-
munohistochemical levels of STK15 expression were related to
various clinicopathologic parameters and long-term follow-up
data in a cohort of 205 patients with bladder cancer. Strong
staining indicative of STK15 overexpression could be identified
in approximately 50% of all bladder tumors and was strongly
associated with high histologic grade, a nonpapillary growth
pattern, invasion, and aneuploidy (Table 2), all indicators of
highly aggressive human bladder cancer. STK15 overexpression
was detected in 76.9% of invasive, high-grade aneuploid bladder
Fig. 2. Quantitation of the copy number of the STK15 gene and chromosomes
3, 17, 20, and 21 in 16 human bladder cancers by fluorescence in situ hybrid-
ization (FISH). a–d) Examples of dual-color FISH, demonstrating localization
of the STK15 probe (green signals) and a chromosome 20p arm-specific probe
(red signals). a) Diploid copy number of STK15 in a normal urothelial cell.
b) Low level of STK15 gene amplification in tumor No. 5, a diploid/near-diploid
urothelial carcinoma cell containing four copies of the STK15 gene and two
copies of the p arm-specific probe. c) High level of STK15 gene amplification
in tumor No. 10, a urothelial carcinoma cell containing seven copies of STK15
and only two copies of the p arm-specific probe. d) Polysomy of chromosome 20
in tumor No. 14, a urothelial carcinoma cell containing multiple copies of STK15
and of the p arm-specific probe. e) Quantitative FISH analysis of STK15 copy
number in 16 human bladder cancers. FISH signals were counted in 100–200
intact tumor nuclei. The percentage of cells showing low (3–4 copies) and high
(>4 copies) amplification levels of STK15 in the individual cases are shown. In
diploid/near-diploid tumors, approximately 40%–50% of the cells have a low
level of STK15 gene amplification and less than 20% have a high level. In the
majority of aneuploid tumors, more than 20% of the cells have high levels of
STK15 amplification. f) FISH analysis of chromosomes 3, 17, 20, and 21 copy
number using centromere-specific probes of the same cases as shown in b–e.
Tumors with low levels of STK15 amplification show no or minimal increases
in chromosome copy numbers. Tumors with high levels of STK15 gene ampli-
fication show increases in chromosome copy numbers in all but tumor No. 16.
In tumor No. 16, pronounced aneuploidy was not associated with a major in-
crease in STK15 copy number, although this tumor showed strong overexpres-
sion of STK15 protein by immunohistochemical staining. g) The analysis of
degree of aneuploidy (DNA index; the ratio of the total nuclear DNA content of
tumor cells to that of a diploid standard) in relation to STK15 gene amplification
levels (3–4 copies versus >4 copies). Values greater than 1 indicate an increase
in total nuclear content and reflect the degree of aneuploidy. Bars represent
mean DNA index ± 95% confidence interval (CI). Statistical significance of the
difference between the two groups was determined by a two-sided Student’s t
test. h) Degree of chromosomal instability (increased chromosome copy num-
ber) in relation to STK15 gene amplification levels (3–4 copies versus >4 cop-
ies). Bars represent mean chromosome copy number ± standard deviation. Sta-
tistical significance of the difference between the two groups for each
chromosome was determined by two-sided Student’s t tests. i) Scatter plot show-
ing the relationship among the proportion of cells with high STK15 gene am-
plification levels (>4 copies) and average chromosome copy number in 16 tu-
mors studied by FISH. The regression line shows a predicted average
chromosome copy number (Spearman’s correlation coefficient  0.82). Solid
bars within FISH images shown in a–d indicate 5 m. Note: Although the tumor
numbers within the figure are consistent with each other, they do not correspond
to the tumor numbers used in Fig. 1.
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cancers but in only 7.5% of superficial bladder tumors. Overall,
superficial noninvasive tumors that overexpressed STK15 pro-
tein were highly aneuploid and had a high likelihood of progres-
sion to invasive clinically aggressive disease. Tumors that over-
expressed the STK15 protein had an increased propensity for
distant metastasis and decreased patient survival (Table 3).
Kaplan–Meier analyses revealed that patients whose bladder
cancers overexpressed STK15 protein had dramatically de-
creased metastasis-free and overall survival compared with pa-
tients whose tumors did not overexpress STK15 protein (Fig. 3
and Table 4).
DISCUSSION
Genetic instability has been suggested to be responsible for
malignant transformation and tumor progression (42–44). Re-
cent studies have shown that several forms of genetic instability
associated with distinct molecular mechanisms can be found in
human tumors (41–48). The most well characterized form of
instability involves the inactivation of DNA mismatch repair
genes, which is reflected in the expansion or shortening of mi-
crosatellite sequences; however, this form of instability can be
documented in only a minor proportion of tumors, which typi-
Table 2. Relationship between STK15 overexpression and pathologic features
of 205 human bladder cancers
Pathologic features
Tumors with STK15
overexpression, %* P value†
Growth pattern
Papillary 20.4 <.001
Nonpapillary 76.9
Histologic grade‡
Low grade (grade 1–2) 3.9 <.001
High grade (grade 3) 74.0
Invasion
Superficial (Ta–T1a) 7.5 <.001
Invasive (T1b–T4) 73.6
DNA ploidy§
Diploid/near-diploid 0 <.001
Aneuploid 76.6
*STK15 overexpression was determined by immunohistochemical analysis.
STK15 expression in at least 20% of tumor cells was considered overexpressed
or positive.
†Chi-square tests of association.
‡Histologic grading is according to World Health Organization (WHO)
grading system for bladder tumors (33). Tumors were staged according to the
Tumor–Node–Metastasis (TNM) classification of malignant tumors with
T1a–b substaging (34,35).
§DNA ploidy was determined by measuring the total nuclear DNA content of
cells with the Feulgen reaction. A DNA index was generated by the ratio of total
nuclear DNA content of tumor cells to that of a diploid standard. The tumors
with a DNA index of 0.9–1.2 were classified as diploid/near-diploid. The tumors
with a DNA index of greater than 1.2 were classified as aneuploid.
Table 3. Relationship between STK15 overexpression and clinical behavior of
205 human bladder cancers
Clinical behavior Proportion of patients, % P value
Recurrence
STK15 − 74 .057*
STK15 + 71
Distant metastases
STK15 − 13 <.001*
STK15 + 31
5-y survival
STK15 − 68 <.001*
STK15 + 19
Overall survival
STK15 − 73 <.001†
STK15 + 27
*Chi-square tests of association.
†Kaplan–Meier two-sided log-rank test.
Fig. 3. Kaplan–Meier plots showing metastasis-free (a) and overall survival (b)
of 205 patients with bladder cancer, grouped on the basis of tumor STK15
overexpression. STK15 expression was determined on the basis of immunohis-
tochemical analysis in which tumors were classified as positive when more than
20% of the tumor cells showed strong cytoplasmic STK15 staining. P values are
derived from two-sided log-rank tests. a) For patients with no STK15 overex-
pression, the mean metastasis-free survival was 145.1 months (95% confidence
interval [CI] 132.8 months to 157.5 months); 1-year survival was 88.3% (95%
CI 81.6% to 94.9%); 3-year survival was 83.9% (95% CI 75.7% to 92.0%).
For patients with STK15 overexpression, the mean metastasis-free survival was
79.1 months (95% CI  63.9 months to 94.3 months); 1-year survival was
74.2% (95% CI  60.0% to 88.4%); 3-year survival was 69.1% (95% CI 
50.9% to 87.4%). b) For patients with no STK15 overexpression, the mean
overall survival was 133.5 months (95% CI  119.8 months to 147.4 months);
1-year survival was 84.3% (95% CI  77.0% to 91.5%); 3-year survival was
77.5% (95% CI  68.7% to 86.4%). For patients with STK15 overexpression,
the mean overall survival was 48.7 months (95% CI  34.8 months to 62.5
months); 1-year survival was 51.9% (95% CI  37.3% to 66.5%); 3-year sur-
vival was 35.8% (95% CI  18.8% to 52.8%).
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cally retain a diploid or near-diploid karyotype (45,46). Inacti-
vation of mitotic spindle checkpoint genes, such as BUB and
MAD2, have been implicated in aneuploidy, but mutant BUB
genes and decreased expression of MAD2 protein could be
documented in only a small fraction of aneuploid solid tumors
(47,48). Our finding of STK15 amplification in virtually all
bladder tumors tested by FISH and the strong association of the
gene amplification and overexpression levels with the degree of
aneuploidy suggests that STK15 may play an important role in
bladder carcinogenesis by contributing to the development of
aneuploid cell populations with aggressive phenotypes.
Although a high level of STK15 expression appeared to be
common in bladder tumors, approximately 30% of highly aneu-
ploid aggressive bladder tumors showed no evidence of STK15
overexpression. This suggests that, in a fraction of bladder tu-
mors, other genes are associated with the development of aneu-
ploidy. In fact, two recently identified mammalian members of
the aurora kinase family, AuroraB (also referred to as Aurora1/
Aik2) and AuroraC (also referred to as Aik3), have increased
expression levels in several human cancers (49,50). Because of
the complexity of genomic alterations seen in the vast majority
of solid tumors, it is unlikely that STK15 is the sole contributor
to the development of aneuploidy. Rather, overexpressed STK15
most likely acts in concert with the products of other genes
involved in the process of chromosomal segregation.
It is important to note that the STK15 gene is localized to
chromosome 20q13 and was identified by searching for overex-
pressed sequences from the long arm of chromosome 20, which
is frequently amplified in a wide range of human cancers (51).
Increased copies of 20q have also been associated with aggres-
sive variants of several epithelial and mesenchymal malignan-
cies including bladder cancer (52,53). The 20q region is typi-
cally amplified in high-grade invasive urothelial carcinomas of
the bladder, virtually all of which exhibit pronounced aneu-
ploidy (54–56). Moreover, in vitro studies have shown that vi-
rally transformed human urothelial cells contain an increased
copy number of chromosome 20, suggesting that the amplifica-
tion of genetic material on this chromosome may play a role in
early phases of urothelial neoplasia (57). All these features sup-
port the hypothesis that STK15 represents a major target gene
within the 20q amplicon. The role of this gene in human carci-
nogenesis must be viewed, however, in concert with those of
other genes mapped to the same region, which may be amplified
and overexpressed together with or independently of STK15.
Several such genes were recently identified and include AIB1,
CAS, TFAP2C, ZNF217, NABC1, and CYP24 (58–62). The
involvement of this segment of the genome in human carcino-
genesis was further confirmed by the recent mapping of human
chromosome 20 with microarray comparative genomic hybrid-
ization technology, which revealed several discontinuous gains
and losses along the 20q arm that varied in individual tumors (63).
In summary, on the basis of our results, we hypothesize that
high expression of STK15 disrupts the signaling cascade that
regulates equal segregation of chromosomes, which leads to pro-
nounced aneuploidy and an aggressive phenotype. Thus, expres-
sion profiling of this kinase may have the potential to be of
diagnostic and prognostic significance. Identification of addi-
tional genes involved in the STK15 regulatory pathway should
further improve our understanding of mechanisms causing an-
euploidy in human cancers. In fact, we have recently proposed
that protein phosphatase type 1 acts in a feedback regulatory
pathway with STK15 kinase to control chromosome segregation
during mitosis (64). Abrogation of this regulation was shown to
cause anomalous mitotic segregation of chromosomes. The
genes involved in the STK15 pathway and their products may
also be attractive novel targets for the development of detection
markers and therapeutic strategies. Such approaches might be
particularly useful in early premalignant phases of human neo-
plasia, providing tools for monitoring and, ultimately, even pre-
venting chromosomal instability.
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